stockrow
Saturday 7 November 2026
Export BMRA’s income statement to Excel — free account
Biomerica, Inc.
BMRA Healthcare Medical Devices
Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025.
- Revenue
- −8.33%
- EPS
- −46,350.0%
- Free cash flow
- −199.3%
Quarter to August 2026, against a year earlier
1.61
0.00
0.00%
Follow BMRA
Alert me
| Older periods | Nov '25 | Feb '26 | May '26 | Aug '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.47 | 1.41 | 1.54 | 1.59 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.63) | (4.89) | (7.54) | (8.59) | |
P/B ratio |
1.48 | 1.84 | 2.62 | 1.89 | |
Price to Tangible BV |
1.56 | 1.98 | 2.84 | 2.00 | |
EV/Sales |
0.90 | 1.10 | 1.25 | 0.96 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.36) | (1.51) | (1.63) | (1.05) | |
EV/FCF |
(1.32) | (1.46) | (1.60) | (1.04) | |
Quick Ratio |
2.18 | 1.46 | 0.84 | 1.28 | |
Current Ratio |
3.25 | 2.64 | 1.62 | 1.91 | |
Net Debt/EBITDA |
2.00 | 1.12 | 0.92 | 2.38 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.67 | 0.71 | 0.70 | 0.58 | |
Operating CF/Net income |
0.75 | 0.95 | 0.80 | 0.65 | |
Capex/Depreciation |
0.00 | (0.18) | 0.16 | 0.00 | |
Research and Development Expense of Revenue |
15.95% | 18.03% | 23.40% | 16.28% | |
Selling, General and Administrative Expense of Revenue |
101.74% | 109.02% | 143.49% | 88.85% | |
Intangible Assets out of Total Assets |
0.04 | 0.05 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
9.67% | 13.68% | 10.39% | 10.59% | |
Graham Net Nets |
0.55 | 0.42 | (0.02) | 0.14 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(68.12%) | (73.87%) | (53.78%) | (78.47%) | |
Free Cash Flow Yield |
(46.47%) | (53.64%) | (50.54%) | (58.23%) | |
Revenue per Share |
0.42 | 0.33 | 0.30 | 0.38 | |
Operating CF per Share |
(0.34) | (0.42) | (0.31) | (0.24) | |
Capex per Share |
0.00 | (0.01) | 0.01 | 0.00 | |
Free Cash Flow per Share |
(0.34) | (0.42) | (0.31) | (0.24) | |
Cash per Share |
0.87 | 0.44 | 0.45 | 0.83 | |
Shareholders Equity per Share |
1.53 | 1.10 | 0.90 | 1.11 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.53 | 1.10 | 0.90 | 1.11 | |
Free Cash Flow |
(0.99) | (1.27) | (0.89) | (0.80) | |
Working Capital |
3.59 | 2.56 | 1.54 | 2.57 | |
Capital Expenditures |
— | (0.02) | 0.02 | — | |
Net Current Asset Value |
3.59 | 2.56 | (0.11) | 0.99 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.02 | (0.02) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.14 | 1.10 | 0.76 | 1.05 | |
Average Payables |
0.79 | 0.68 | 0.92 | 1.09 | |
Average Inventory |
1.66 | 1.65 | 1.60 | 1.55 | |
Average Assets |
6.65 | 6.13 | 6.35 | 7.46 | |
Average Common Equity |
4.77 | 4.43 | 3.37 | 4.40 |
Columns are period end dates · fundamentals updated 2 Nov 2026